We are proud to announce today of our strategic partnership with STONE Diagnostics, a leading provider of laboratory services in the United States. STONE Diagnostics will provide Physicians and their patients end to end service to enable Physicians to assess chronic liver disease with Fibronostics’ benchmark product, LIVERFASt™. STONE Diagnostics‘ combination of scaled operational excellence and leading digital capabilities leveraging MyHealthAI is ideal and vital to serve doctors using LIVERFASt™ to screen, identify and monitor *MAFLD/MASH patients.
Find out more: https://www.prnewswire.com/news-releases/fibronostics-announces-partnership-with-stone-diagnostics-301952321.html
